TY - JOUR
TI - Natural killer cell cytotoxicity is a predictor of outcome for patients with high risk myelodysplastic syndrome and oligoblastic acute myeloid leukemia treated with azacytidine
AU - Tsirogianni, M.
AU - Grigoriou, E.
AU - Kapsimalli, V.
AU - Dagla, K.
AU - Stamouli, M.
AU - Gkirkas, K.
AU - Konsta, E.
AU - Karagiannidou, A.
AU - Gkodopoulos, K.
AU - Stavroulaki, G.
AU - Pappa, V.
AU - Angelopoulou, M.
AU - Lowdell, M.
AU - Tsirigotis, P.
JO - Clinical Lymphoma Myeloma and Leukemia
PY - 2019
VL - 60
TODO - 10
SP - 2457-2463
PB - Taylor and Francis Ltd.
SN - null
TODO - 10.1080/10428194.2019.1581935
TODO - azacitidine;  biological marker;  azacitidine;  biological marker, acute myeloid leukemia;  adult;  aged;  Article;  cancer survival;  chronic myelomonocytic leukemia;  clinical article;  clinical trial;  controlled study;  female;  high risk patient;  human;  human cell;  immunomodulation;  male;  myelodysplastic syndrome;  myeloid-derived suppressor cell;  natural killer cell;  outcome assessment;  overall survival;  priority journal;  prospective study;  regulatory T lymphocyte;  treatment outcome;  treatment response;  very elderly;  acute myeloid leukemia;  cytotoxicity;  immunology;  lymphocyte subpopulation;  metabolism;  middle aged;  mortality;  myelodysplastic syndrome;  natural killer cell;  prognosis;  receiver operating characteristic;  tumor cell line, Aged;  Aged, 80 and over;  Azacitidine;  Biomarkers;  Cell Line, Tumor;  Cytotoxicity, Immunologic;  Female;  Humans;  Killer Cells, Natural;  Leukemia, Myeloid, Acute;  Lymphocyte Subsets;  Male;  Middle Aged;  Myelodysplastic Syndromes;  Prognosis;  ROC Curve
TODO - The aim of the present study was to identify biomarkers predictive of the outcome of patients with high-risk myelodysplastic syndrome and oligoblastic acute myeloid leukemia (AML) treated with 5-azacytidine (AZA). We prospectively examined the association between NK-cytotoxic activity, myeloid-derived suppressor cells (MDSCs), and T-regulatory cells (Tregs) on the overall survival (OS) of patients. Patients with NK-cytotoxicity above a critical threshold had a longer duration of response and survived longer than patients with severe impairment of NK-cytotoxicity. The numbers of MDSCs, and Tregs in the PB of patients after a short exposure to AZA were not different from normal donors. In conclusion, the results of our study suggest that the therapeutic activity of AZA is at least partly mediated by an immunomodulatory effect. To our knowledge, this is the first study reported so far, that shows a positive correlation between NK cytotoxicity and OS of AZA-treated patients. © 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.
ER -